Association Between Cognition, Health Related Quality of Life, and Costs in a Population at Risk for Cognitive Decline

Niels Janssen*, Ron L Handels, Anders Wimo, Riitta Antikainen, Tiina Laatikainen, Hilkka Soininen, Timo Strandberg, Jaakko Tuomilehto, Miia Kivipelto, Silvia M A A Evers, Frans R J Verhey, Tiia Ngandu

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: The association between health-related quality of life (HRQoL) and care costs in people at risk for cognitive decline is not well understood. Studying this association could reveal the potential benefits of increasing HRQoL and reducing care costs by improving cognition. Objective: In this exploratory data analysis we investigated the association between cognition, HRQoL utilities and costs in a well-functioning population at risk for cognitive decline. Methods: An exploratory data analysis was conducted using longitudinal 2-year data from the FINGER study (n = 1,120). A change score analysis was applied using HRQoL utilities and total medical care costs as outcome. HRQoL utilities were derived from the Short Form Health Survey-36 (SF-36). Total care costs comprised visits to a general practitioner, medical specialist, nurse, and days at hospital. Analyses were adjusted for activities of daily living (ADL) and depressive symptoms. Results: Although univariable analysis showed an association between cognition and HRQoL utilities, multivariable analysis showed no association between cognition, HRQoL utilities and total care costs. A one-unit increase in ADL limitations was associated with a-0.006 (p < 0.001) decrease in HRQoL utilities and a one-unit increase in depressive symptoms was associated with a-0.004 (p < 0.001) decrease in HRQoL utilities. Conclusion: The level of cognition in people at-risk for cognitive decline does not seem to be associated with HRQoL utilities. Future research should examine the level at which cognitive decline starts to affect HRQoL and care costs. Ideally, this would be done by means of cross-validation in populations with various stages of cognitive functioning and decline.

Original languageEnglish
Pages (from-to)623-632
Number of pages10
JournalJournal of Alzheimer's Disease
Volume89
Issue number2
Early online date26 Jul 2022
DOIs
Publication statusPublished - 26 Jul 2022

Cite this